Research programme: lipocalin derived cancer immunotherapeutics - Pieris/ Roche
Latest Information Update: 15 Dec 2015
At a glance
- Originator Pieris
- Developer Pieris; Roche
- Class Lipocalins
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer